Insider Selling: Billiontoone (NASDAQ:BLLN) Insider Sells 20,000 Shares

Billiontoone, Inc. (NASDAQ:BLLN) insider Thomas Lynch sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $99.99, for a total transaction of $1,999,800.00. Following the transaction, the insider directly owned 700 shares of the company’s stock, valued at $69,993. The trade was a 96.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Stock Performance

BLLN traded down $0.65 during mid-day trading on Thursday, reaching $98.51. 729,077 shares of the company traded hands, compared to its average volume of 562,068. The stock has a market capitalization of $4.65 billion and a P/E ratio of 141.66. Billiontoone, Inc. has a 52-week low of $61.96 and a 52-week high of $150.44. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. The company’s fifty day moving average price is $112.07 and its 200-day moving average price is $95.79.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, meeting analysts’ consensus estimates of $0.15. The company had revenue of $109.45 million during the quarter. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. On average, sell-side analysts expect that Billiontoone, Inc. will post 0.83 EPS for the current year.

Hedge Funds Weigh In On Billiontoone

A number of hedge funds have recently made changes to their positions in BLLN. The Manufacturers Life Insurance Company lifted its holdings in Billiontoone by 151.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 30,506 shares of the company’s stock worth $2,408,000 after purchasing an additional 18,389 shares in the last quarter. Sei Investments Co. purchased a new stake in Billiontoone during the 1st quarter valued at approximately $1,058,000. Wasatch Advisors LP raised its position in shares of Billiontoone by 40.2% during the second quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock valued at $62,160,000 after buying an additional 148,446 shares during the last quarter. Emerald Mutual Fund Advisers Trust lifted its holdings in shares of Billiontoone by 11.9% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 132,206 shares of the company’s stock worth $10,436,000 after buying an additional 14,072 shares in the last quarter. Finally, Perceptive Advisors LLC lifted its holdings in shares of Billiontoone by 26.1% in the first quarter. Perceptive Advisors LLC now owns 91,812 shares of the company’s stock worth $7,248,000 after buying an additional 19,000 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts have weighed in on BLLN shares. Zacks Research downgraded shares of Billiontoone from a “hold” rating to a “strong sell” rating in a research report on Monday, August 31st. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Canaccord Genuity Group initiated coverage on Billiontoone in a report on Wednesday, September 2nd. They set a “buy” rating and a $120.00 price target for the company. JPMorgan Chase & Co. reduced their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a research report on Thursday, August 6th. Finally, BTIG Research reduced their target price on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $125.88.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.